(firstQuint)A Study on SANGUINATE for the Reduction of Delayed Graft Function in Kidney Transplant Patients.

 Sixty (60) adult subjects who will be recipients of a donation after brain death (DBD) donor kidney and who meet all eligibility criteria will be randomized 1:1 within 48 hours prior to transplant surgery to receive: two infusions of SANGUINATE at a dose of 320 mg/kg or placebo on the day of surgery and approximately 24 hours after surgery.

 Patients will be hospitalized for up to 5 days and the study duration will be 30 days.

.

 A Study on SANGUINATE for the Reduction of Delayed Graft Function in Kidney Transplant Patients@highlight

Safety and efficacy study of SANGUINATE on reduction of delayed graft function (DGF) in patients who will be recipients of a donation after brain death (DBD) donor kidney.

